þ Type-1T helper (Th1) cells secreting interferon-g (IFN-g) appear to play an essential role in promoting durable 
Introduction
Previous studies have shown that melanoma represents a prototype for neoplasia responsive to immunotherapy and serves as a suitable model system for the development of antitumor vaccines. 1, 2 While most vaccine studies have focused solely on effector CD8
þ T-cell responses as surrogates for clinical cancer responses, it is now clear that antitumor CD4 þ T cells regulate the quality, magnitude and durability of CD8 þ cytotoxic T lymphocyte (CTL) immunity in vivo, [3] [4] [5] and that the Type-1T
helper (Th1) cytokine, interferon-g (IFN-g), plays an essential role in this response. Th1-type CD4 þ T cells secrete IFN-g and may mediate delayed-type hypersensitivity responses that can lead to enhanced cross-presentation of tumor antigens by host antigen-presenting cells (APCs), 6 and consequent epitope spreading in the evolving antitumor T-cell repertoire. 7, 8 Furthermore, CD4 þ T cells may mediate direct tumoricidal activity via tumor necrosis factor (TNF) family ligand members and can inhibit tumor angiogenesis via locoregional production of IFN-g. [9] [10] [11] [12] Antitumor Th1-type CD4 þ T cells, however, appear inhibited in many cancer patients, 5, 13, 14 as reflected by decreased proliferation and T-cell receptor signaling, 15 as well as by increased frequencies and activity of regulatory T cells. 16, 17 Whereas Th1-type responses have been associated with spontaneous or therapy-induced regression of tumor lesions, 14, 18 tumor-infiltrating lymphocytes isolated from patients with progressive lesions have been generally reported to exhibit dominant Th2-type (secreting interleukin (IL)-4, IL-5) or regulatory (Th3)-type (secreting IL-10, TGF-b1) responses. 13 Our group has previously shown that peripheral blood CD4 þ T cells isolated from melanoma or renal cell carcinoma patients with active disease exhibit highly skewed, non-Type-1 CD4 þ T-cell reactivity against epitopes derived from tumor antigens, such as MAGE-A6. 19 These findings contrast noticeably with normal donors and cancer patients who exhibit no current evidence of disease as a consequence of therapeutic intervention, in whom either mixed Th1/Th2-type or strongly Th1-polarized responses to MAGE-A6 peptides occur, respectively. 19 These results strongly suggest that the future immune-based therapies must overcome existing deficiencies in Type-1 antitumor CD4 þ T-cell responses in cancer patients with active disease in order to be clinically effective.
IL-12p70 and IL-18 are crucial Th1-type cytokines that synergize in promoting IFN-g secretion from, and proliferation of, CD4
þ T effector cells. 20, 21 IL-12p70 induces T-cell surface expression of the IL-18 receptor (IL-18R) by naı¨ve T cells, 22 whereas IL-18, an IL-1 family member, potentiates the differentiation of Th1 cells instigated by IL-12p70. 23 We hypothesized that dysfunctional antitumor Th1-type responses in cancer patients with active disease might be recovered/enhanced by in vitro stimulation (IVS) of patient CD4 þ T cells using vaccines containing autologous dendritic cells (DCs) engineered to secrete IL-12p70 and/or IL-18. This gene therapy approach could not only prove capable of supporting Type-1 immunity, but would have the potential to obviate toxicities previously observed for systemic application IL-12p70 alone [24] [25] [26] or IL-12p70 combined with IL-18. 27 Indeed, our group has previously shown in murine models that DCs engineered to secrete both IL-12p70 and IL-18 ex vivo, and subsequently injected intratumorally, promote acute tumor rejection in concert with enhanced Th1-type immunity and determinant spreading in the curative antitumor CTL repertoire. 28 In the current study, we generated and applied novel recombinant adenoviral (rAd) vectors encoding human IL-12p70 (Ad. 
Materials and methods

Recombinant adenoviral vectors
The Ad.C5, Ad.IL-12 and Ad.IL-18 E1-and E3-deleted adenoviral vector encoding the human interleukin-12 (hIL-12) p70 and interleukin-18 (hIL-18) cDNAs were constructed through Cre-lox recombination with reagents generously provided by Dr S Hardy (Somatix, Alameda, CA). The pre-pro leader sequence of human granulocytemacrophage coony-stimulating factor (GM-CSF) was fused to the 5 0 end of the mature hIL-18 cDNA in order to facilitate secretion of bioactive IL-18 by infected cells. SalI-NotI fragments containing p40-IRES-p35 or modified mature form of hIL18 cDNAs were inserted into the shuttle vector, pAdlox. Recombinant adenoviruses were generated by co-transfection of SfiI-digested pAdloxhIL-12 or pAdlox-hIL-18 and C5 helper virus DNA into the adenoviral packaging cell line CRE8 that expresses Cre recombinase, as described previously. 29 Recombinant adenoviruses were propagated on CRE8 cells, purified by cesium chloride density-gradient centrifugation and subsequent dialysis, before storage in 3% threalose at À801C.
Cytokine enzyme-linked immunosorbent assays Adenoviral function and cytokine bioactivity were evaluated using enzyme-linked immunosorbent assays (ELISAs) for hIL-12p70 (Pharmingen, San Diego, CA), hIL-18 (R&D Systems, Minneapolis, MN) and hIFN-g (antibody pairs from Mabtech, Mariemont, OH), as per the manufacturer's protocols. The lower limits of detection for these assays were 4.0, 12.5 and 4.0 pg/ml, respectively.
MAGE-A6 protein and peptides
Recombinant MAGE-A6 protein (rMAGE) and MAGE-A6 peptides (MAGE-A6 121À144 , 30 MAGE-A6 140À170 , 30 MAGE-A6 246À263 30 and MAGE-A6 280À302 were pulsed onto DCs to generate stimulator cells for in vitro sensitization of T cells. Non-transformed TOP10 (Invitrogen, Carlsbad, CA) bacteria were grown and processed in an identical manner as for rMAGE purification, with the processed/eluted material (TOP10) later used as a negative control in ELISPOT readouts. 31 Isolation of patient and normal donor peripheral blood mononuclear cells Peripheral blood was obtained by venipuncture from normal donors or melanoma patients a single time with consent, under an International Review Board-approved protocol. Peripheral blood was diluted 1:2 with phosphate-buffered saline (PBS), applied to Ficoll-Hypaque gradients (Cellgro; Mediatech Inc., Herndon, VA) and centrifuged at 550 g for 25 min at room temperature. Peripheral blood mononuclear cells (PBMC) were recovered from the buoyant interface and washed at least three times with PBS in order to remove residual platelets as well as Ficoll-Hypaque. Donor HLA-DR4 status was determined using a specific anti-HLA-DR4mAb 359-F10 and fluorescence-activated cell sorter (FACS) analysis, as described previously. 19, 30 Only PBMC determined to be HLA-DR4 þ were used in these experiments. The eight melanoma patients analyzed were between 31 and 83 years of age. Six of the eight patients (except Mel4 and Mel 6) tested were male, with all but Mel4 and Mel5 having active disease status at the time of blood draw. Blood was obtained at least 1 month after patient treatment with surgery alone (all), surgery þ chemotherapy (Mel1, Mel2) or surgery þ radiotherapy (Mel 1). Disease stage at the time of initial diagnosis for each patient is listed in Table 1 .
Dendritic cell generation
Following Ficoll density separation, PBMCs were plated in T75 culture flasks (Costar, Cambridge, MA) flasks in AIM-V (GIBCO-BRL, Gaithersburg, MD) medium for 60 min at 371C. Following incubation, non-adherent (NA) cells were removed from flasks by gentle washing with PBS, and cryopreserved in freezing media (10% dimethylsulfoxide (Sigma-Aldrich, St Louis, MO), 90% fetal bovine serum (Invitrogen)) using controlled-rate freezing technique in a À801C freezer. Adherent monocytes were cultured at 371C and 5% CO 2 in DC medium (AIM-V supplemented with 500 U/ml GM-CSF (Sargramostim; Amgen, Thousand Oaks, CA) and 1000 U/ml IL-4 (Schering Plough; Kenilworth, NJ)) for 5-7 days, as described previously.
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CD4
þ T-cell isolation On the day of establishing DC-T-cell cultures, NA cells were thawed at 371C and washed in AIM-V medium. CD4 þ T cells were isolated from the NA cells by magnetic cell sorting (Miltenyi Biotech, Auburn, CA) according to the manufacturer's protocol.
In vitro stimulation Dendritic cells were used as stimulators of autologous T cells and were either not infected or infected with rAd Abbreviations: DC, dendritic cells; IFN-g, interferon-g; NT, not tested; rMAGE, recombinant MAGE-A6; Th1, Type-1T helper. CD4 + T cells isolated from the peripheral blood of eight melanoma patients were tested for their ability to be stimulated by, and react against, the indicated MAGE-A6 peptide epitopes. Patient disease stage is cited, with (*) indicating patients who had no evidence of disease at the time of blood donation. CD4 + T cells were stimulated a single time in vitro using autologous DC pulsed with a mixture of 10 mg/ml of each MAGE-A6 peptide (Peptide Mix), rMAGE protein or control peptide/protein. 32 The impact of viral infection on DC viability (Annexin-V from Invitrogen, Carlsbad, CA) and maturation status (upregulation of CD83, major histocompatibility complex class I and II, CD80, CD86) was assessed by FACS analyses, as described previously. 32 After infections, DCs were incubated for 3 h in 1 ml of T-cell media along with peptides (10 mg/ml) or rMAGE (5 mg/ml). Once pulsed with antigen, DC were co-cultured with autologous CD4 þ T-lymphocytes at a 1:10 (DC:T cell) ratio in T-cell media.
ELISPOT On day 11 of T-cell cultures, the frequencies of peptidespecific CD4
þ T-cell responders were measured using T2.DR4 cells as APCs in commercial human IFN-g ELISPOT assays, as described previously. 19, 30 The number of peptide-specific CD4 þ T-cell responders was always compared to the background number of IFN-g spots produced against APCs pulsed with the malarial circumsporozooite CS 326À345 peptide (for peptide-based assays) or with the TOP10-processed bacterial lysate in the analyses of the natural processing and presentation of rMAGE protein-derived peptides. Positive control wells contained T cells cultured in the presence of 10 mg/ml phytohemagglutinin (Sigma-Aldrich).
Statistical analyses
The statistical significance of differenced between T-cell responses was determined using a Student's t-test, with differences with an associated Po0.05 considered significant.
Results
Recombinant adenoviral vectors encoding IL-12p70 and mature IL-18 efficiently transduce dendritic cells resulting in the secretion of bioactive cytokines Adenoviral vectors were initially evaluated for their ability to infect tumor cells, as well as immature DCs. Viral load used for infections was optimized for protein production and cell survival (data not shown). It was determined that an MOI of 100 for Ad.IL-12 and an MOI of 250 for Ad.IL-18 were optimal for efficient DC gene transduction. As described previously, 30 adenoviral infection at these MOI did not induce terminal DC maturation (as determined by alterations in cell surface expression of maturation markers), nor did infections alter the capacity of these cells to mature subsequently in response to a cocktail of stimuli including IL-1, IL-6 and TNF-a (data not shown).
The secretion of transgene-encoded IL-12p70 and IL-18 protein was confirmed using specific ELISAs applied to supernatant samples harvested from cells infected in vitro. After infection of 10 6 DCs with Ad.IL-12 or Ad.IL-18, and subsequent incubation for 48 h at 371C, cell supernatants contained approximately 10-20 ng/ml of IL-12p70 and 200-300 pg/ml of IL-18, on average. Representative data are depicted in Figure 1 . Interestingly, although DCs and tumor cells displayed comparable infection efficiencies, the amount of IL-18 produced by gene-modified tumor cells was approximately 10-fold higher than that observed for infected DCs (despite comparable efficiencies of transduction, data not shown), suggesting that differential post-translational regulation of IL-18 protein secretion may occur in these two cell types.
The bioactivity of these transgene products was determined indirectly by assessing the ability of infected cell supernatant samples to subsequently induce IFN-g secretion from responder human PBMC. To minimize the impact of additional non-virus-induced factors on our assay results (i.e. other than IL-12p70 or IL-18), we analyzed supernatants from infected murine CMS4 tumor cells, 28 to stimulate IFN-g secretion from freshly isolated PBMC. CMS4 supernatants were titrated on responder cells in order to discern any dose-dependent induction of IFN-g secretion. Both the IL-12p70 (Figure 1c ) and IL-18 ( Figure 1d ) transgene products were observed to induce IFN-g secretion from PBMC in a dose-dependent manner, whereas control Ad-infected CMS4 supernatants did not. þ T cells. A single round of in vitro stimulation was employed in order to most directly discern the ability of DC stimulations to amplify Th1-type responses against these epitopes (i.e. by avoiding extended in vitro cultures where the impact on existent immunity would be less interpretable). Eleven days after the initiation of the IVS protocol, IFN-g ELISPOT assays were performed to enumerate peptide-specific Th1-type CD4 þ T-cell responses ( Figure 2 ). Although individual adenoviral infections had little effect on the induction of responses (except for ND1, where Ad.IL-12 infection of DCs led to enhanced Th1-type responsiveness to a single MAGE-A6 121À144 peptide), co-infection of DCs with both Ad.IL-12 and Ad.IL-18 led to enhanced stimulation of Type-1 CD4 þ T-cell reactivity against the MAGE-A6 246À263 peptide in both donors, as well as against the MAGE-A6 121À144 peptide in ND2. Based on the reproducible superiority of DC.IL-12/18 vs all other DC cohorts in promoting specific Type-1 anti-MAGE-A6 CD4 þ T-cell responses in vitro among six normal donors analyzed (Figure 2 and data not shown), this modality was systematically adopted for all consequent analyses involving patient materials. 246À263 , and in some indicated cases, MAGE-A6 280À302 ) or with rMAGE, then added to cultures of autologous CD4 þ T cells. Eleven days after the initiation of the IVS protocol, IFN-g ELISPOT assays were performed in order to enumerate the frequencies of peptide-specific Th1-type CD4 þ T-cell responders. Peptide-pulsed DC.IL-12/18 enhanced the number/frequency of responder T cells as well as the magnitude of mean responses, especially against the MAGE-A6 121À144 and MAGE-A6 280À302 epitopes, whereas peptide stimulations with control, uninfected DCs were ineffective in modulating specific CD4 þ T responses (Table 1) . Similarly, rMAGE-pulsed DC.IL-12/18 were more effective than protein-pulsed, uninfected DCs in stimulating epitope-specific CD4 þ Tcell responses in vitro. Anti-MAGE-A6 121À144 , -MAGE-A6 280À302 as well as -MAGE-A6 246À263 mean CD4 þ T-cell responses were significantly enhanced following stimulation with rMAGE-pulsed DC.IL-12/18 (Table 1) . Indeed, all of the donors evaluated responded to at least one MAGE-A6 epitope in the ELISPOT assay following stimulation with rMAGE protein-loaded DC.IL-12/18. In the majority of cases, protein-pulsed uninfected DCs appeared more effective than peptide-pulsed, uninfected DCs in promoting Type-1 responses (Table 1) . Overall, these results suggest the superior immunostimulatory effectiveness of DC.IL-12/18 (vs control DC) loaded with either synthetic MAGE-A6 peptides or in particular, rMAGE protein, in stimulating specific Th1-type CD4 þ T-cell responses from patients with melanoma in vitro.
Dendritic cells co-infected with
Discussion
In this study, we generated a novel, functional adenoviral vector encoding the mature form of hIL-18 protein, as well as a functional adenoviral vector encoding for hIL-12p70 protein, and analyzed their ability to infect human DCs, thereby yielding a superior in vitro 'vaccine' Engineered DCs promote specific Type-1 immunity L Vujanovic et al capable of promoting tumor-specific Type-1 CD4 þ T-cell responses. Consistent with previous reports by our group and others evaluating adenoviral infection of DCs, 28, 32, 33 neither vector induced terminal DC maturation following infection (based on phenotypic criteria), resulting in engineered DCs that were functionally competent to uptake and process soluble antigens (such as rMAGE).
To directly assess the Th1-stimulating properties associated with Ad.IL-12 and Ad.IL-18 infection on DCs, and not alternate stimuli, engineered DCs were not concomitantly or consequently matured using cytokine/ prostanoid cocktails. Given the desire to interpret the acute effects of DC-based stimulations on a perceived Type-1 dysfunctional T-cell repertoire in cancer patients, 19, 34 we analyzed peripheral blood CD4 þ T cells isolated from HLA-DR4 þ normal donors activated after a single round of in vitro sensitization. We evaluated normal donor and patient CD4 þ T cells stimulated with uninfected DCs or Ad-engineered DCs loaded with MAGE-A6 peptides or protein for their ability to secrete IFN-g when restimulated (in ELISPOT assays) with three known HLA-DR4-restricted MAGE-A6-derived (MAGE-A6 121À144 , MAGE-A6 140À170 , MAGE-A6 246À263 epitopes; 19,30 and a novel poly-DR-presented MAGE-A6 280À302 epitopes. 31 Our results suggest that DC.IL-12/18 were the most effective APCs for the promotion of Th1-type responses (that may be associated with tumor regression in situ; Tatsumi et al.
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) among those tested in this study. In contrast, DCs infected with either Ad.IL-12 (DC.IL-12) or Ad.IL-18 (DC.IL-18) exhibited immunostimulatory capacities that were no greater than those noted for DCs infected with Ad.C5 (DC.C5). The improved efficacy associated with DC.IL-12/18 stimulator cells may reflect the knowledge that IL-12p70 is required to induce T-cell surface expression of the IL-18R on naı¨ve T cells, 22 whereas the IL-1 family member, IL-18, potentiates the differentiation of Th1 cells instigated by IL-12p70, 23 and that IL-12 and IL-18 synergize in the activation of T cells and induction of IFN-g secretion from T-cell responders. 20, 21 To evaluate the efficacy of this approach in the cancer setting, monocyte-derived DCs were generated from eight HLA-DR4 þ melanoma patients and used to stimulate autologous CD4 þ T cells in vitro. Uninfected DCs were compared to DC.IL-12/18 for their ability to stimulate Th1-type responses after being pulsed with synthetic peptides or rMAGE protein. We observed that DC.IL-12/18 were more effective in stimulating peptidespecific Th1-type responses than uninfected DCs, especially when loaded with rMAGE protein, in which case, every patient (regardless of clinical staging and the presence/absence of disease at the time of analysis) evaluated responded to at least one of the previously defined, naturally processed/presented MAGE-A6-derived epitopes evaluated following in vitro sensitization. This suggests that DC.IL-12/18 may be suitable for use in vaccines designed to over-ride the general Type-1 dysfunction in CD4 þ T-cell responses to tumor antigens observed in many cancer patients with advanced stage disease, 16, 17, 19, 34 in support of therapeutic immunity in the clinical setting.
In conjunction with the knowledge that IL-18 is a chemoattractant for myeloid and plasmacytoid DCs, 35, 36 one could also hypothesize that protein-pulsed DC.IL-12/ 18, if injected s.c. or intratumorally, might not only induce Th1-type responses but also attract additional host DCs into the vaccine/tumor microenvironment. Within this microenvironment, such a paradigm could enhance consequent tumor cell apoptosis, tumor antigen uptake and the cross-priming of antitumor T cells in vivo. 28 In summary, we have generated a novel Ad.hIL-18, and have shown that when used in conjunction with Ad.hIL-12 to co-infect human DCs, a vaccine platform (DC.IL-12/18) is produced that may be loaded with a recombinant tumor antigen or its derivative peptides in order to induce effectively specific Th1-type CD4 þ T-cell responses in vitro from normal donors and patients with melanoma. Further investigation is warranted to determine whether this strategy can be translated into the clinic as a therapeutic vaccine, either as a stand-alone modality or when administered in combination with agents that ablate or neutralize functional regulatory T-cell activity Engineered DCs promote specific Type-1 immunity L Vujanovic et al in situ, [37] [38] [39] in order to potentiate optimally therapeutic Type-1 antitumor immunity in vivo.
